A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
At a glance
- Drugs Neratinib (Primary) ; Fulvestrant; Trastuzumab
- Indications Advanced breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms MutHER
- 02 May 2019 Planned number of patients changed from 77 to 80.
- 02 May 2019 Planned End Date changed from 31 Dec 2021 to 31 May 2024.
- 02 May 2019 Planned primary completion date changed from 30 Jun 2020 to 30 Nov 2022.